Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $63.86 USD
Change Today +0.05 / 0.08%
Volume 183.5K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Snapshot

Open
$63.40
Previous Close
$63.81
Day High
$63.98
Day Low
$63.27
52 Week High
08/6/15 - $68.00
52 Week Low
10/16/14 - $45.67
Market Cap
10.9B
Average Volume 10 Days
536.3K
EPS TTM
--
Shares Outstanding
170.5M
EX-Date
07/8/15
P/E TM
--
Dividend
$0.31
Dividend Yield
0.49%
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDY)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDY) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDY) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

20,373 Employees
Last Reported Date: 06/17/15
Founded in 1984

doctor reddy's lab-adr (RDY) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Managin...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2015.

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Limited Announces Executive Change

Dr. Reddy's Laboratories Limited announced that Umang Vohra, is moving out of the company and has consequently stepped down from the position of Executive Vice President and Head of North America Generics. Alok Sonig Executive Vice President and Head of India Generics will now take over as Executive Vice President and Head of North America Generics. MV Ramana, who is currently Executive Vice President- Emerging Market has assumed additional charges and is now Executive Vice President and head Branded Market(India and Emerging countries).

Dr. Reddy's Laboratories Ltd. Launches Generic Version of Parkinson's Drug in US

Dr. Reddy's Laboratories Ltd. announced the U.S. launch of Parkinson's treatment Pramipexole dihydrochloride extended release tablets, a generic form of Mirapex ER. The release in the U.S. follows the approval by the US Food and Drug Administration. The tablets are available in 0.375 mg, 0.75 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

Dr. Reddy's Laboratories Ltd. Announces the Launch of PRAMIPEXOLE Dihydrochloride Extended Release Tablets

Dr. Reddy's Laboratories Ltd. announced that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of MIRAPEX ER (pramipexole dihydrochloride). Extended-Release Tablets in the US market on August 11, 2015, following the approval by the United States Food & Drug Administration (USFDA). The MIRAPEX ER® brand and generic had U.S. sales of approximately $48.3 Million MAT for the most recent twelve months ending in June 2015 according to IMS Health. Dr. Reddy's PRAMIPEXOLE dihydrochloride extended-release tablets mg are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $63.86 USD +0.05

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 756.40 INR 0.00
Cadila Healthcare Ltd 1,929 INR 0.00
Croda International PLC 2,892 GBp +42.00
Sigma-Aldrich Corp $139.55 USD -0.10
Symrise AG €53.64 EUR +0.075
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 29.1x
Price/Sales 4.4x
Price/Book 6.0x
Price/Cash Flow 29.0x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.